SCHEMBL4248571

SCHEMBL4248571

Cc1cccc(-c2cc(C(=O)O)c3cnccc3n2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.60
ALDH1A1 P00352 5/20 0.60
HSD17B10 Q99714 2/20 0.60
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
LMNA P02545 5/20 0.57
HTT P42858 1/20 0.57
DHODH Q02127 6/20 0.56
SMN1; SMN2 Q16637 2/20 0.52
PDE10A Q9Y233 1/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52
AKR1C1 Q04828 1/20 0.52
KMO O15229 1/20 0.50
GAA P10253 1/20 0.48
TP53 P04637 2/20 0.47
MAPT P10636 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
HIF1A Q16665 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251041 0.86 KDM4E (0.69) KDM4EALDH1A1HSD17B10LMNAHTT
SCHEMBL4248489 0.85 DHODH (0.64) KDM4EALDH1A1HSD17B10LMNAHTT
SCHEMBL4254130 0.85 ALDH1A1 (0.61) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL4248498 0.85 ALDH1A1 (0.54) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL4248564 0.84 MEN1 (0.61) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL8614836 0.84 KDM4E (0.75) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL14034400 0.82 MEN1 (0.49) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL4246561 0.81 DHODH (0.55) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL18320684 0.81 KDM4E (0.78) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL4248520 0.80 ACHE (0.49) KDM4EALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-20050171141-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2005-08-04 US disclosed
WO-2005056552-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171141-A1 Modulators of muscarinic receptors CHRM3, CHRM2, CHRM4 KDM4E 4060/4885ALDH1A1 2677/4885HSD17B10 3175/4885
US-20090042928-A1 Modulators of muscarinic receptors CHRM3, CHRM2, CHRM4 KDM4E 4060/4885ALDH1A1 2677/4885HSD17B10 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.